LABCORP HOLDINGS INC.
NYSE: LH·Burlington, North Carolina·CIK 0000920148
- Price
- $372.46
- Base IV
- $135.89
Valuation snapshot
At $372.46, the price is above even our bull case of $214.02.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $135.89
- 36% of the price · range $68.35–$214.02
- Price vs base case
- 174% above
- $372.46 against $135.89
- Base case · our researched forecast, 2026-11-13See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $68.35 to bull $214.02. Values per share.
Price against each value
- Bear case
- $68.35
- Price 445% above
- No growth
- …
- —
- Base case
- $135.89
- Price 174% above
What does Labcorp do?
Labcorp provides diagnostic testing and laboratory services to help healthcare providers, pharmaceutical companies, and researchers make clinical decisions and develop new drugs.
It brought in $14.6B of sales in the 12 months to Sep 2026.
Led by Adam Schechter, Chairman, President and Chief Executive Officer since 2019. Labcorp Leadership Team
- Industry
- Healthcare
- Based in
- Burlington, North Carolina
- Trades on
- NYSE as LH
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 7¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 71¢ of every dollar.
- Making what it sells71¢
- Sales, marketing and admin16¢
- Everything else it takes to operate3¢
- Interest and other costs2¢
- Tax2¢
- Left as profit7¢
Who pays Labcorp, and for what?
Labcorp runs laboratories that test patient samples and help doctors make care decisions. It also performs laboratory work for drug companies, from early research through clinical trials. It earns revenue when these customers, insurers, government programs or patients pay for its services.
Its payers include health insurers, hospitals, medical practices, employers, government health programs, patients and drug developers.
Diagnostics Laboratories
78%Routine and specialized medical tests, including blood, cancer and genetic tests.
Biopharma Laboratory Services
22%Laboratory research and testing for companies developing drugs and diagnostics.
Where its work physically happens, beyond headquarters:
- Indianapolis Central Laboratory — Indianapolis, United States. Labcorp's website names Indianapolis as a flagship Biopharma Laboratory Services site, and the FY2025 10-K lists it as a leased primary facility, so it carries much of the central-lab testing behind Labcorp's clinical-trial revenue.
- Madison Early Development Laboratories — Madison, United States. Madison is an owned flagship Biopharma site that does preclinical toxicology, bioanalytical, drug-metabolism and CMC work, which makes it central to Labcorp's early-development revenue and capacity.
- Phoenix Diagnostics Laboratory — Phoenix, United States. Phoenix is an owned primary laboratory in the Diagnostics segment, Labcorp's largest segment by revenue, and gives the company high-volume testing capacity in the western U.S. (cited from the FY2024 10-K because its listing in the FY2025 10-K could not be confirmed).
- Greenfield Biopharma Facility — Greenfield, United States. Greenfield is an owned primary facility listed among Labcorp's lab sites in the 2025 10-K and adds owned laboratory capacity near the Indianapolis cluster.
- Harrogate Laboratory — Harrogate, United Kingdom. Harrogate is an owned primary facility listed in the FY2025 10-K and anchors Labcorp's European laboratory capacity for biopharma clients.
How is the business doing?
Sales have barely moved over 5 years, from $14B in 2020 to $14B in 2025.
Running the business leaves about 10¢ of each sales dollar as operating profit, down from 17¢ in 2020.
After paying for its upkeep and new investment, it had $1.3B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Labcorp says it exists to improve people's health and lives through testing, drug development support and technology.
“To improve health and improve lives”
Who is responsible for the plan?
Adam SchechterChairman, President and Chief Executive OfficerLeads Labcorp as chief executive officer and chairs its Board of Directors. As CEO he is responsible for the whole company, including both its Diagnostics Laboratories and Biopharma Laboratory Services businesses.
- Brian CaveneyExecutive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer
Leads the Biopharma Laboratory Services segment and serves as the company's Chief Medical and Scientific Officer. Biopharma Laboratory Services is the segment that sells laboratory testing and research services to biopharmaceutical customers, one of Labcorp's two main sources of revenue.
- Bola OyegunwaExecutive Vice President and Chief Information and Technology Officer
Leads Labcorp's enterprise information technology, including laboratory systems, corporate systems, data and technology. The laboratory and data systems he oversees support the testing services Labcorp sells through its Diagnostics and Biopharma Laboratory Services businesses.
Roles checked November 13, 2026.
What management says it is working on now:
Partner with health systems
Labcorp wants to run more testing for hospitals and regional laboratories that choose to focus their own resources on patient care.
Labcorp 2025 Form 10-KExpand specialized tests
It is developing tests in cancer, women's health, autoimmune disease and neurology, and aims to make these tests available more widely.
Labcorp 2025 Form 10-KSupport new therapies
It is building laboratory capacity to help drug companies develop cell and gene therapies.
Labcorp 2025 Form 10-KMake testing easier for patients
It is expanding direct-to-consumer tests, home sample collection and digital tools for booking visits and viewing results.
Labcorp 2025 Form 10-KReach more international markets
It plans to use its global laboratory network and drug-company relationships to bring specialized tests to more countries.
Labcorp 2025 Form 10-K
- Total revenue, 2026
- $14.779 billion to $14.887 billion
- Labcorp third-quarter 2026 results and guidance
- Diagnostics Laboratories revenue, 2026
- $11.475 billion to $11.551 billion
- Labcorp third-quarter 2026 results and guidance
- Biopharma Laboratory Services revenue, 2026
- $3.328 billion to $3.358 billion
- Labcorp third-quarter 2026 results and guidance
- Adjusted operating margin improvement, by the end of 2029
- 0.75 to 1.5 percentage points
- Labcorp 2026 Investor Day
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 7% more than a year earlier. The year before, quarters averaged 6%.
Its operating margin is about where it was a year ago, 11¢ per sales dollar.
Since Oct 2026 the share price has risen 1%, from $368.16 to $372.46.
Recently
October 28, 2026
Enterprise revenue growth, quarterly YoY changed to 6.9%
Labcorp Q3 2026 results (8-K)October 28, 2026
GAAP operating margin, quarterly changed to 10.5%
Labcorp Q3 2026 results (8-K)December 31, 2025
Annual Free Cash Flow changed to $1.2B
Labcorp FY 2025 Form 10-K Consolidated Statements of Cash Flows
Coming up
By the end of 2026
Expanded cervical screening
Labcorp and Waters plan to offer an HPV test through Labcorp's national network, with options for samples collected by clinicians or patients.
Waters and Labcorp HPV testing announcementExpected by early 2027
Prenatal testing acquisition
Labcorp has agreed to buy Myriad Genetics' prenatal testing business. The purchase still needs regulatory clearance and other closing conditions.
Myriad Genetics and Labcorp acquisition announcementNo closing date announced
Millennium Health acquisition
Labcorp has agreed to acquire Millennium Health, which specializes in drug testing. Closing depends on regulatory approvals and other conditions.
Labcorp Millennium Health acquisition announcement
Our own estimate moved too: the base case went from $203.55 to $135.89 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Lower payments for tests
Insurers and government programs may pay less for tests or limit which tests they cover. Further Medicare rate cuts are scheduled to resume in 2027.
From the company's own filingsWould hit how fast sales growLabcorp 2025 Form 10-K
Intense competition
Hospital labs, independent labs and drug research providers compete with Labcorp on price, speed and test offerings. Losing customers or contracts could slow growth.
From the company's own filingsWould hit how fast sales growLabcorp 2025 Form 10-K
Drug research spending
Labcorp's drug development work depends on customers funding research. Customers can also delay, reduce or end studies, leaving Labcorp with less work.
From the company's own filingsWould hit how fast sales growLabcorp 2025 Form 10-K
Acquisition integration
Labcorp buys laboratories to expand its services and reach. Combining their staff, facilities and systems may cost more or deliver less than expected.
From the company's own filingsWould hit how much of each sale it keepsLabcorp 2025 Form 10-K
Changing test technology
New home or doctor's-office tests could reduce demand for commercial laboratories. Labcorp also needs to keep developing or licensing useful new tests.
From the company's own filingsWould hit how fast sales growLabcorp 2025 Form 10-K
Data security
A breach of patient information or a failure of Labcorp's or a supplier's computer systems could interrupt services and lead to legal costs or fines.
From the company's own filingsWould hit how much of each sale it keepsLabcorp 2025 Form 10-K
Organic growth was 5.5% in Q3, below the 6.9% reported figure.
From our researchWould hit how fast sales growInvesting.com Q3 2026 call transcript
Q3 2026 GAAP operating margin was 10.6%, below Q3 2025's 11.1%.
From our researchWould hit how much of each sale it keepsLabcorp Q3 2026 results (8-K Ex.99.1)
Is it a good business?
From 2016 to 2025 it earned between 4% and 23% on its shareholders' equity, a median of 13%.
Over 10 years its operating margin ranged from 6¢ to 20¢ per sales dollar, a median of 12¢. Gross margin ran from 28¢ to 35¢.
It bought back shares: the count fell 2.5% in a year, so each remaining share owns a slightly bigger slice.
It owes $5.7B more than it holds in cash, about 3.8 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $372.46. Our put its value between $68.35 and $214.02, with $135.89 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $68.35
This scenario assumes Labcorp's recent growth of about 6–7% a year fades to around 3% as acquisitions slow and insurers keep squeezing test prices, with profits staying near today's levels.
Base case, $135.89
This scenario assumes Labcorp keeps growing roughly in line with its recent 6–7% pace in the near term, slowing gently to about 4%, while cost savings slowly lift its profits.
Bull case, $214.02
This scenario assumes Labcorp keeps up its recent growth of roughly 7% a year for longer, helped by recovering demand from drug companies and more hospital lab deals, while its profits per dollar of sales climb steadily.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 174%
For Labcorp to be worth today's $372.46, sales would need to grow about 24.0% a year. We assume 5.0%. Over the last 5 years, sales shrank 2.5% a year.
Or, if sales grow 5.0% as we assume, the price works with a profit margin of 26.9% (we assume 12.5%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 24.0% a year?
Try your own numbersWe're moderately sure of this range: it scores 59 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $135.89 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average5.0%
- Operating margin12.5%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$135.89 -63.5%

